Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | RAB9A | P51151 | 6/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509244 | 0.82 | ADORA3 (0.51) | KDM4ESMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL12325734 | 0.82 | KDM4E (0.65) | KDM4ESMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL16509242 | 0.82 | KDM4E (0.49) | KDM4ESMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL14922007 | 0.81 | KDM4E (0.69) | KDM4ESMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL4589453 | 0.79 | ALDH1A1 (0.57) | KDM4ESMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL2326375 | 0.78 | BRD4 (0.45) | KDM4ESMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL6475362 | 0.78 | ALDH1A1 (0.74) | KDM4ESMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL2326385 | 0.78 | ALDH1A1 (0.59) | KDM4ESMN1; SMN2RAB9ACYP11B1CYP11B2 | |
| SCHEMBL12325957 | 0.77 | KDM4E (0.68) | KDM4ESMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL3639863 | 0.77 | KDM4E (1.00) | KDM4ESMN1; SMN2NPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009005551-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-7405235-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405235-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | KDM4E 360/4885SMN1; SMN2 4868/4885NPC1 3055/4885 |
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | CREBBP, JUN, IRF3 | KDM4E 500/4885SMN1; SMN2 4876/4885NPC1 3138/4885 |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JUN, CREBBP, TFEB | KDM4E 360/4885SMN1; SMN2 4868/4885NPC1 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.